BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sinha S, Castillo V, Espinoza CR, Tindle C, Fonseca AG, Dan JM, Katkar GD, Das S, Sahoo D, Ghosh P. COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis. EBioMedicine 2022;82:104185. [PMID: 35870428 DOI: 10.1016/j.ebiom.2022.104185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ali G, Zhang M, Chang J, Zhao R, Jin Y, Ji HL. PAI-1 regulates AT2-mediated re-alveolarization and ion permeability. Res Sq 2023:rs. [PMID: 36909505 DOI: 10.21203/rs.3.rs-2289657/v1] [Reference Citation Analysis]
2 Zhang X, Hu X, Zhang Y, Liu B, Pan H, Liu Z, Yao Z, Zhu Q, Wu C, Shen T. Impaired autophagy-accelerated senescence of alveolar type II epithelial cells drives pulmonary fibrosis induced by single-walled carbon nanotubes. J Nanobiotechnology 2023;21:69. [PMID: 36849924 DOI: 10.1186/s12951-023-01821-6] [Reference Citation Analysis]
3 Mehta P, Rosas IO, Singer M. Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity. Intensive Care Med 2022;48:1803-6. [PMID: 36074167 DOI: 10.1007/s00134-022-06877-w] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]